California State Teachers Retirement System Has $39.18 Million Stock Position in DexCom, Inc. $DXCM

California State Teachers Retirement System lessened its stake in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) by 1.0% in the second quarter, according to its most recent Form 13F filing with the SEC. The fund owned 581,686 shares of the medical device company's stock after selling 5,875 shares during the period. California State Teachers Retirement System owned about 0.15% of DexCom worth $39,176,552 as of its most recent SEC filing.

Several other hedge funds also recently made changes to their positions in DXCM. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its stake in shares of DexCom by 15.6% during the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 11,261,876 shares of the medical device company's stock valued at $758,487,000 after purchasing an additional 1,515,702 shares during the period. Geode Capital Management LLC lifted its holdings in DexCom by 0.4% in the 4th quarter. Geode Capital Management LLC now owns 11,006,183 shares of the medical device company's stock valued at $727,842,000 after purchasing an additional 42,411 shares in the last quarter. Norges Bank purchased a new stake in DexCom in the fourth quarter valued at approximately $483,356,000. Janus Henderson Group PLC raised its holdings in DexCom by 32.3% during the first quarter. Janus Henderson Group PLC now owns 2,644,539 shares of the medical device company's stock worth $166,077,000 after purchasing an additional 645,534 shares in the last quarter. Finally, Legal & General Group Plc acquired a new stake in shares of DexCom in the 2nd quarter valued at approximately $173,237,000. 97.75% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other DexCom news, EVP Jereme Sylvain sold 3,638 shares of the business's stock in a transaction that occurred on Thursday, September 10th. The shares were sold at an average price of $83.27, for a total value of $302,936.26. Following the completion of the transaction, the executive vice president owned 146,828 shares of the company's stock, valued at $12,226,367.56. The trade was a 2.42% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Sadie Stern sold 2,565 shares of DexCom stock in a transaction dated Thursday, August 27th. The stock was sold at an average price of $88.37, for a total value of $226,669.05. Following the completion of the sale, the executive vice president owned 126,043 shares of the company's stock, valued at $11,138,419.91. The trade was a 1.99% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 63,715 shares of company stock worth $4,828,695 over the last 90 days. 0.28% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on the company. Royal Bank Of Canada upped their price target on DexCom from $85.00 to $90.00 and gave the company an "outperform" rating in a research report on Friday, July 31st. TD Cowen reissued a "buy" rating on shares of DexCom in a research note on Friday, July 31st. Piper Sandler reissued an "overweight" rating and set a $95.00 target price (up from $88.00) on shares of DexCom in a report on Friday, July 31st. Bank of America reduced their target price on DexCom from $100.00 to $80.00 and set a "buy" rating for the company in a research note on Monday, May 18th. Finally, Truist Financial set a $93.00 price target on shares of DexCom and gave the company a "buy" rating in a research report on Friday, July 31st. Two research analysts have rated the stock with a Strong Buy rating, twenty-one have given a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $88.71.

DexCom Stock Up 2.8%

NASDAQ:DXCM traded up $2.39 during midday trading on Tuesday, reaching $87.07. The company had a trading volume of 2,073,862 shares, compared to its average volume of 5,101,973. The firm has a market capitalization of $32.86 billion, a price-to-earnings ratio of 34.41, a PEG ratio of 1.39 and a beta of 1.42. DexCom, Inc. has a 12-month low of $54.11 and a 12-month high of $92.59. The stock's fifty day simple moving average is $82.99 and its 200-day simple moving average is $72.88. The company has a current ratio of 1.73, a quick ratio of 1.43 and a debt-to-equity ratio of 0.47.

DexCom (NASDAQ:DXCM - Get Free Report) last released its earnings results on Thursday, July 30th. The medical device company reported $0.70 earnings per share for the quarter, topping the consensus estimate of $0.61 by $0.09. The firm had revenue of $1.31 billion for the quarter, compared to the consensus estimate of $1.29 billion. DexCom had a return on equity of 35.94% and a net margin of 20.12%.The firm's revenue for the quarter was up 13.1% compared to the same quarter last year. During the same period in the prior year, the business posted $0.48 earnings per share. On average, sell-side analysts anticipate that DexCom, Inc. will post 2.64 earnings per share for the current fiscal year.

About DexCom

DexCom, Inc develops and commercializes continuous glucose monitoring (CGM) systems that measure glucose levels in real time. Its technology is designed to help people with diabetes monitor glucose trends and make more informed treatment and lifestyle decisions without relying solely on traditional fingerstick testing.

The company's products include the Dexcom G7 and Dexcom G6 CGM systems, which use a small wearable sensor, transmitter or integrated sensor, and mobile applications to display glucose data.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.